Search 

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Investment bank focused on Nordic Life Science companies

PHASTAR is a global biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents.

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.